The Saskatchewan Biosimilars Initiative was announced on October 20, 2022, to improve the uptake of biosimilar drugs. The Biosimilars Initiative means that patients will be covered for a biosimilar version of their biologic medication where one is available.
The Biosimilars Initiative includes ten drugs listed on the Saskatchewan Formulary: adalimumab (Humira®), enoxaparin (Lovenox®), etanercept (Enbrel®), filgrastim (Neupogen®), glatiramer (Copaxone®), infliximab (Remicade®), insulin aspart (NovoRapid®), insulin glargine (Lantus®), insulin lispro (Humalog®), and rituximab (Rituxan®). The policy will also apply to future reference biologics as new biosimilars are launched and listed on the Saskatchewan Formulary.
Established patients already receiving a reference biologic drug (or “originator” biologic) with an available biosimilar version will be required to use a biosimilar version by April 30, 2023, in order to maintain coverage under the Saskatchewan Drug Plan.
Physicians, NPs and pharmacists are asked to approach patient questions with evidence-based information to help build patient confidence in the data supporting biosimilar use and transition.
For the most current and up-to-date news regarding this initiative, visit the Biosimilars Initiative website.